Theriva Biologics (NYSEAMERICAN:TOVX) Trading Up 5.2% – Time to Buy?

Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) were up 5.2% on Tuesday . The company traded as high as $0.2187 and last traded at $0.2029. Approximately 6,389,528 shares traded hands during mid-day trading, an increase of 127% from the average daily volume of 2,820,571 shares. The stock had previously closed at $0.1929.

Theriva Biologics Price Performance

The stock’s 50 day moving average price is $0.26 and its 200-day moving average price is $0.38. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $6.57 million, a PE ratio of -0.01 and a beta of 0.34.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.45) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent SEC filing. Institutional investors and hedge funds own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.